Literature DB >> 16504627

The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE).

Shaun G Goodman1, Philippe Gabriel Steg, Kim A Eagle, Keith A A Fox, José López-Sendón, Gilles Montalescot, Andrzej Budaj, Brian M Kennelly, Joel M Gore, Jeanna Allegrone, Christopher B Granger, Enrique P Gurfinkel.   

Abstract

BACKGROUND: The impact and prognostic value of the redefinition of myocardial infarction (MI) with more sensitive markers have not been evaluated prospectively in a large, less selected population with acute coronary syndrome (ACS).
METHODS: We evaluated the attack and case-fatality rates of MI based on initial and/or peak creatine kinase (CK), creatine kinase-MB (CK-MB), and cardiac troponin (the upper limit of normal [ULN] was defined according to the local hospital's standard) in a prospective observational registry of 26,267 patients with ACS admitted to 106 hospitals in 14 countries.
RESULTS: The addition of cardiac troponin-positive status to CK status as a criterion for the diagnosis of MI resulted in as many as 1 in 4 additional patients meeting the redefined criteria. Compared with patients without elevated levels of CK and cardiac troponin, the crude odds for dying during hospitalization were significantly higher for patients with elevated troponin but not CK levels of greater than or equal to the ULN (odds ratio [OR] 2.2, 95% CI 1.6-2.9), those without CK levels >2 times the ULN (OR 2.8, 95% CI 2.2-3.5), and those with nonelevated levels of CK-MB (OR 2.1, 95% CI 1.4-3.2). The addition of cardiac troponin-positive status significantly increased the multivariable-adjusted odds for hospital death in patients with CK < or =2 times the ULN (OR 1.6, 95% CI 1.2-2.1) but not for patients without elevated levels of CK or CK-MB.
CONCLUSIONS: The prognostic value of cardiac troponin, beyond that supplied by CK status or important baseline characteristics, assists in the identification of patients with ACS who are at increased risk for death.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504627     DOI: 10.1016/j.ahj.2005.05.014

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  16 in total

1.  Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI.

Authors:  David D McManus; Joel Gore; Jorge Yarzebski; Frederick Spencer; Darleen Lessard; Robert J Goldberg
Journal:  Am J Med       Date:  2011-01       Impact factor: 4.965

2.  Troponin Release and Reversible Left Ventricular Dysfunction After Transient Pressure Overload.

Authors:  Brian R Weil; Gen Suzuki; Rebeccah F Young; Vijay Iyer; John M Canty
Journal:  J Am Coll Cardiol       Date:  2018-06-26       Impact factor: 24.094

3.  Myocardial infarction after carotid stenting and endarterectomy: results from the carotid revascularization endarterectomy versus stenting trial.

Authors:  Joseph L Blackshear; Donald E Cutlip; Gary S Roubin; Michael D Hill; Pierre P Leimgruber; Richard J Begg; David J Cohen; John F Eidt; Craig R Narins; Ronald J Prineas; Stephen P Glasser; Jenifer H Voeks; Thomas G Brott
Journal:  Circulation       Date:  2011-05-23       Impact factor: 29.690

Review 4.  Theoretical and Practical Aspects in the Use of Bretschneider Cardioplegia.

Authors:  Claudiu Ghiragosian; Marius Harpa; Alexandra Stoica; Flămînd Oltean Sânziana; Radu Bălău; Hussam Al Hussein; Ghiragosian-Rusu Simina Elena; Radu Mircea Neagoe; Horațiu Suciu
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-02

Review 5.  Universal MI definition update for cardiovascular disease.

Authors:  Harvey White; Kristian Thygesen; Joseph S Alpert; Allan Jaffe
Journal:  Curr Cardiol Rep       Date:  2014       Impact factor: 2.931

6.  Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul study.

Authors:  Bill P C Hsieh; Adam M Rogers; Beeya Na; Alan H B Wu; Nelson B Schiller; Mary A Whooley
Journal:  Am Heart J       Date:  2009-10       Impact factor: 4.749

7.  Quartiles of peak troponin are associated with long-term risk of death in type 1 and STEMI, but not in type 2 or NSTEMI patients.

Authors:  Manuel A Gonzalez; Christopher P Porterfield; Dana J Eilen; Rana A Marzouq; Hiren R Patel; Amit A Patel; Summiyah Nasir; Heang M Lim; Joseph D Babb; John D Rose; Wayne E Cascio
Journal:  Clin Cardiol       Date:  2009-10       Impact factor: 2.882

8.  Frequency histograms of three high-sensitivity cardiac troponin assays in a reference population.

Authors:  Hanwool Cho; Hyunjung Kim; Jehoon Lee; Soo-Young Kim; Hae Kyung Lee; Hi Jeong Kwon; Yeongsic Kim
Journal:  J Clin Lab Anal       Date:  2022-04-20       Impact factor: 3.124

9.  Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial.

Authors:  Ting Xu; Qing H Meng; Susan C Gilchrist; Steven H Lin; Ruitao Lin; Tianlin Xu; Sarah A Milgrom; Saumil J Gandhi; Haijun Wu; Yu Zhao; Juan C Lopez-Mattei; Radhe Mohan; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-07-21       Impact factor: 8.013

10.  Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.

Authors:  Derek S Sim; Hsiao Lieu; Patrick Andre
Journal:  Biomark Insights       Date:  2008-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.